-
Proposed bill to support assisted dying in France Lancet Oncol. (IF 51.1) Pub Date : 2024-04-18 Sharmila Devi
-
US EPA sets historic new restrictions on toxic PFAS in drinking water Lancet Oncol. (IF 51.1) Pub Date : 2024-04-18 Bryant Furlow
-
Cancer Workforce Fund launched to address oncology workforce crisis Lancet Oncol. (IF 51.1) Pub Date : 2024-04-12 Emma Wilkinson
-
Nigeria revitalises national cancer response with new initiatives Lancet Oncol. (IF 51.1) Pub Date : 2024-04-12 Paul Adepoju
-
Study bolsters concerns about US FDA accelerated drug approvals Lancet Oncol. (IF 51.1) Pub Date : 2024-04-12 Bryant Furlow
-
Combining enzalutamide and [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer Lancet Oncol. (IF 51.1) Pub Date : 2024-04-12 Nadine Houédé, Kevin Hebert
-
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial Lancet Oncol. (IF 51.1) Pub Date : 2024-04-12 Prof Louise Emmett MD, Shalini Subramaniam MBBS, Megan Crumbaker PhD, Andrew Nguyen MBBS, Prof Anthony M Joshua PhD, Andrew Weickhardt PhD, Prof Sze-Ting Lee PhD, Siobhan Ng MBBS, Roslyn J Francis PhD, Prof Jeffrey C Goh MBBS, David A Pattison MBBS, Thean Hsiang Tan MBBS, Ian D Kirkwood MBBS, Craig Gedye PhD, Natalie K Rutherford MD, Shahneen Sandhu MBBS, Aravind Ravi Kumar MBBS, David Pook MD, Shakher
Enzalutamide and lutetium-177 [Lu]Lu-prostate-specific membrane antigen (PSMA)-617 both improve overall survival in patients with metastatic castration-resistant prostate cancer. Androgen and PSMA receptors have a close intracellular relationship, with data suggesting complementary benefit if targeted concurrently. In this study, we assessed the activity and safety of enzalutamide plus adaptive-dosed
-
Changes in hospital mortality in patients with cancer during the COVID-19 pandemic (ISARIC-CCP-UK): a prospective, multicentre cohort study Lancet Oncol. (IF 51.1) Pub Date : 2024-04-12 Prof Lance Turtle PhD, Sarah Elliot MSc, Thomas M Drake PhD, Mathew Thorpe MSc, Emma G Khoury MB ChB, William Greenhalf PhD, Hayley E Hardwick, Gary Leeming BA, Andy Law PhD, Wilna Oosthuyzen PhD, Riinu Pius PhD, Catherine A Shaw PhD, Prof J Kenneth Baillie FMedSci, Prof Peter J M Openshaw FMedSci, Annemarie B Docherty PhD, Prof Malcolm G Semple PhD, Ewen M Harrison PhD, Prof Carlo Palmieri PhD, ISARIC4C
Patients with cancer are at greater risk of dying from COVID-19 than many other patient groups. However, how this risk evolved during the pandemic remains unclear. We aimed to determine, on the basis of the UK national pandemic protocol, how factors influencing hospital mortality from COVID-19 could differentially affect patients undergoing cancer treatment. We also examined changes in hospital mortality
-
Advisory Group recommendations on priorities for the IARC Monographs Lancet Oncol. (IF 51.1) Pub Date : 2024-04-12 Amy Berrington de González, Scott A Masten, Parveen Bhatti, Renée Turzanski Fortner, Susan Peters, Tiina Santonen, Marianna G Yakubovskaya, Robert Barouki, Silvia B M Barros, Dinesh Barupal, Laura E Beane Freeman, Gloria M Calaf, Joakim Dillner, Karima El Rhazi, Lin Fritschi, Shoji Fukushima, Lode Godderis, Manolis Kogevinas, Dirk W Lachenmeier, Daniele Mandrioli, Mazvita M Muchengeti, Richard T Niemeier
-
Mitotane: a friend or a foe before cabozantinib treatment in adrenocortical cancer? Lancet Oncol. (IF 51.1) Pub Date : 2024-04-09 Margaret E Wierman
-
Cabozantinib in patients with unresectable and progressive metastatic phaeochromocytoma or paraganglioma (the Natalie Trial): a single-arm, phase 2 trial Lancet Oncol. (IF 51.1) Pub Date : 2024-04-09 Prof Camilo Jimenez MD, Prof Mouhammed Amir Habra MD, Matthew T Campbell MD, Gina Tamsen MD, Damaris Cruz-Goldberg MD, James Long PhD, Roland Bassett MS, Prof Robert Dantzer PhD, Vania Balderrama-Brondani MD, Jeena Varghese MD, Prof Yang Lu MD
Metastatic phaeochromocytomas and paragangliomas (MPPGs) are orphan diseases. Up to 50% of MPPGs are associated with germline pathogenic variants of the gene. These tumours and many non-familial MPPGs exhibit a phenotype that is characterised by abnormal angiogenesis. We aimed to assess the activity and safety of cabozantinib, an antiangiogenic multi-tyrosine kinase inhibitor, in patients with MPPGs
-
Cabozantinib monotherapy for advanced adrenocortical carcinoma: a single-arm, phase 2 trial Lancet Oncol. (IF 51.1) Pub Date : 2024-04-09 Matthew T Campbell MD, Vania Balderrama-Brondani MD, Prof Camilo Jimenez MD, Gina Tamsen MD, Prof Leonardo P Marcal MD, Jeena Varghese MD, Amishi Y Shah MD, James P Long PhD, Miao Zhang MD, Joshua Ochieng PhD, Cara Haymaker PhD, Prof Mouhammed Amir Habra MD
Adrenocortical carcinoma is a rare malignancy with poor response to systemic chemotherapy. Mitotane is the only approved therapy for adrenocortical carcinoma. Cabozantinib is a multikinase inhibitor approved in multiple malignancies. This is the first prospective trial to explore the anti-tumour activity, safety, and pharmacokinetic profile of cabozantinib in patients with advanced adrenocortical carcinoma
-
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial Lancet Oncol. (IF 51.1) Pub Date : 2024-04-09 Ana Oaknin MD, Kathleen Moore MD, Prof Tim Meyer MD, José López-Picazo González MD, Lot A Devriese MD, Prof Asim Amin MD, Christopher D Lao MD, Valentina Boni MD, Prof William H Sharfman MD, Jong Chul Park MD, Makoto Tahara MD, Prof Suzanne L Topalian MD, Manuel Magallanes MD, Alejandro Molina Alavez MD, Tariq Aziz Khan MD, Catherine Copigneaux PhD, Michelle Lee MS, Charlie Garnett-Benson PhD, Xuya
In preliminary findings from the recurrent or metastatic cervical cancer cohort of CheckMate 358, nivolumab showed durable anti-tumour responses, and the combination of nivolumab plus ipilimumab showed promising clinical activity. Here, we report long-term outcomes from this cohort. CheckMate 358 was a phase 1–2, open-label, multicohort trial. The metastatic cervical cancer cohort enrolled patients
-
Expansion of radiotherapy access in Ethiopia Lancet Oncol. (IF 51.1) Pub Date : 2024-04-05 Manjulika Das
-
MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II–III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study Lancet Oncol. (IF 51.1) Pub Date : 2024-04-05 Anna van der Voort MD, Fleur M Louis MD, Mette S van Ramshorst MD, Rob Kessels PhD, Ingrid A Mandjes MSc, Inge Kemper MANP, Mariette J Agterof MD, Wim A van der Steeg MD, Joan B Heijns MD, Marlies L van Bekkum MD, Ester J Siemerink MD, Philomeen M Kuijer MD, Astrid Scholten MD, Prof Jelle Wesseling MD, Prof Marie-Jeanne T F D Vrancken Peeters MD, Ritse M Mann MD, Prof Gabe S Sonke MD, Dutch Breast
Patients with stage II–III HER2-positive breast cancer have good outcomes with the combination of neoadjuvant chemotherapy and HER2-targeted agents. Although increasing the number of chemotherapy cycles improves pathological complete response rates, early complete responses are common. We investigated whether the duration of chemotherapy could be tailored on the basis of radiological response. TRAIN-3
-
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial Lancet Oncol. (IF 51.1) Pub Date : 2024-03-29 Prof Jean-Pascal Machiels MD, Yungan Tao MD, Prof Lisa Licitra MD, Prof Barbara Burtness MD, Prof Makoto Tahara MD, Prof Danny Rischin MD, Gustavo Alves MD, Iane Pinto Figueiredo Lima MD, Brett G M Hughes MBBS, Yoann Pointreau MD, Prof Sercan Aksoy MD, Prof Simon Laban MD, Prof Richard Greil MD, Prof Martin Burian MD, Marcin Hetnał MD, Prof Jean-Pierre Delord MD, Ricard Mesía MD, Miren Taberna MD,
Despite multimodal therapy, 5-year overall survival for locally advanced head and neck squamous cell carcinoma (HNSCC) is about 50%. We assessed the addition of pembrolizumab to concurrent chemoradiotherapy for locally advanced HNSCC. In the randomised, double-blind, phase 3 KEYNOTE-412 trial, participants with newly diagnosed, high-risk, unresected locally advanced HNSCC from 130 medical centres globally
-
UK tobacco and vapes bill one step closer Lancet Oncol. (IF 51.1) Pub Date : 2024-03-28 Priya Venkatesan
-
Environmental pollution and cancer risk in La Oraya, Peru Lancet Oncol. (IF 51.1) Pub Date : 2024-03-28 Manjulika Das
-
-
Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study Lancet Oncol. (IF 51.1) Pub Date : 2024-03-26 Ayse Bahar Ercan BSc, Melyssa Aronson MS, Nicholas R Fernandez BSc, Yuan Chang BSc, Adrian Levine MD, Zhihui Amy Liu PhD, Logine Negm BSc, Melissa Edwards PhD, Vanessa Bianchi PhD, Lucie Stengs BSc, Jiil Chung PhD, Abeer Al-Battashi MD, Agnes Reschke MD, Alex Lion DO, Alia Ahmad FRCPCH, Alvaro Lassaletta MD, Alyssa T Reddy MD, Amir F Al-Darraji MD, Amish C Shah MD, An Van Damme MD, Anne Bendel MD,
Constitutional mismatch repair deficiency (CMMRD) syndrome is a rare and aggressive cancer predisposition syndrome. Because a scarcity of data on this condition contributes to management challenges and poor outcomes, we aimed to describe the clinical spectrum, cancer biology, and impact of genetics on patient survival in CMMRD. In this cohort study, we collected cross-sectional and longitudinal data
-
Arsenic contamination and cancer risk in Bangladesh Lancet Oncol. (IF 51.1) Pub Date : 2024-03-21 Manjulika Das
-
-
1 in 9 USA cancer diagnoses missed during 2020 COVID-19 pandemic Lancet Oncol. (IF 51.1) Pub Date : 2024-03-21 Tony Kirby
-
Massive US cybersecurity breach highlights perils of health-care consolidation Lancet Oncol. (IF 51.1) Pub Date : 2024-03-14 Bryant Furlow
-
Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial Lancet Oncol. (IF 51.1) Pub Date : 2024-03-08 Arnon P Kater MD, Önder Arslan MD, Fatih Demirkan MD, Yair Herishanu MD, Burhan Ferhanoglu MD, Marcos Gonzalez Diaz MD, Brian Leber MD, Marco Montillo MD, Panayiotis Panayiotidis MD, Davide Rossi PhD, Alan Skarbnik MD, Adrian Tempescul PhD, Mehmet Turgut MD, Clemens H Mellink PhD, Anne-Marie F van der Kevie-Kersemaekers PhD, Stuart Lanham PhD, Ben Sale MSc, Luis Del Rio MSc, Relja Popovic MD, Brenda
Most patients with chronic lymphocytic leukaemia progress after treatment or retreatment with targeted therapy or chemoimmunotherapy and have limited subsequent treatment options. Response levels to the single-agent venetoclax in the relapsed setting is unknown. We aimed to assess venetoclax activity in patients with or without previous B-cell receptor-associated kinase inhibitor (BCRi) treatment.
-
Alabama Supreme Court's “extrauterine children” decision alarms oncologists and fertility experts Lancet Oncol. (IF 51.1) Pub Date : 2024-03-07 Bryant Furlow
-
Non-communicable diseases in humanitarian settings Lancet Oncol. (IF 51.1) Pub Date : 2024-03-07 Talha Burki
-
Innovation in gynaecological cancer: highlighting global disparities Lancet Oncol. (IF 51.1) Pub Date : 2024-03-07 Maria Kyrgiou, Sarah Bowden, Lynette Denny, Anna Fagotti, Nadim R Abu-Rustum, Pedro T Ramirez, Denis Querleu
-
Correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer: an FDA pooled analysis Lancet Oncol. (IF 51.1) Pub Date : 2024-03-05 Bernardo Haddock Lobo Goulart MD, Sirisha L Mushti PhD, Somak Chatterjee PhD, Erin Larkins MD, Pallavi S Mishra-Kalyani PhD, Richard Pazdur MD, Paul G Kluetz MD, Harpreet Singh MD
Radiographic changes might not fully capture the treatment effects of immune checkpoint inhibitors (ICIs). We aimed to assess correlations of overall response rate and progression-free survival with overall survival in trials of ICIs for metastatic non-small-cell lung cancer (NSCLC). To assess trial-level and patient-level correlations of overall response rate and progression-free survival with overall
-
Indonesia and the Philippines take steps to control cancer Lancet Oncol. (IF 51.1) Pub Date : 2024-02-29 Manjulika Das
-
CALLA trial: immunotherapy in locally advanced cervical cancer – Authors' reply Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Bradley J Monk, Jyoti Mayadev
-
Safe and effective cancer care: how long must we wait? Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 The Lancet Oncology
-
Optimal imaging before local therapy of colorectal liver metastases – Authors' reply Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Burak Görgec, Jasper P Sijberden, Rutger-Jan Swijnenburg, Åsmund A Fretland, Cornelis Verhoef, Marc G Besselink, Jaap Stoker
-
Uncovering causal clues in the development of second primary cancers – Authors' reply Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Trille Kristina Kjaer, Christoffer Johansen, Susanne Oksbjerg Dalton
-
A pan-European total cancer prevalence canvas: a benchmark for advancing strategic interventions Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Shahrokh F Shariat
-
The Radiation Planning Assistant: addressing the global gap in radiotherapy services Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Laurence E Court
-
Harnessing stereotactic precision in the fight against primary kidney cancer: time for a randomised trial? Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Daniel X Yang, Raquibul Hannan
-
Joseph Lubega, Director of Global HOPE—building paediatric cancer care in sub-Saharan Africa Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Emma Wilkinson
-
Endpoints in human papillomavirus-related oropharyngeal cancer trials Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Marshall Posner, Scott A Roof
-
Optimal imaging before local therapy of colorectal liver metastases Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Antony Haddad, Mateo Lendoire, Iwan Paolucci, HyunSeon Christine Kang, Jean-Nicolas Vauthey
-
The need for speed: recovering undersampled MRI scans for glioma imaging Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Frederik Barkhof, Geoff JM Parker
-
Optimal imaging before local therapy of colorectal liver metastases Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Vincenza Granata, Antonella Petrillo, Sergio Venanzio Setola, Francesco Izzo, Roberta Fusco
-
Use of radiotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Sean McPhail PhD, Matthew E Barclay PhD, Ruth Swann PhD, Shane A Johnson MA, Riaz Alvi MSc, Andriana Barisic MPH, Oliver Bucher MSc, Nicola Creighton MAppStat, Cheryl A Denny MPH, Ron A Dewar MSc, David W Donnelly PhD, Jeff J Dowden MSc, Laura Downie PhD, Norah Finn MSc, Prof Anna T Gavin FFPHM, Steven Habbous PhD, Prof Dyfed W Huws MSc, S Eshwar Kumar FRCR, Leon May MPH, Carol A McClure PhD, David
There is little evidence on variation in radiotherapy use in different countries, although it is a key treatment modality for some patients with cancer. Here we aimed to examine such variation. This population-based study used data from Norway, the four UK nations (England, Northern Ireland, Scotland, and Wales), nine Canadian provinces (Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland
-
Use of chemotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Sean McPhail PhD, Matthew E Barclay PhD, Shane A Johnson MA, Ruth Swann PhD, Riaz Alvi MSc, Andriana Barisic MPH, Oliver Bucher MSc, Nicola Creighton MAppStat, Cheryl A Denny MPH, Ron A Dewar MSc, David W Donnelly PhD, Jeff J Dowden MSc, Laura Downie PhD, Norah Finn MSc, Prof Anna T Gavin FFPHM, Steven Habbous PhD, Prof Dyfed W Huws MSc, Leon May MPH, Carol A McClure PhD, Bjørn Møller PhD, Grace Musto
There are few data on international variation in chemotherapy use, despite it being a key treatment type for some patients with cancer. Here, we aimed to examine the presence and size of such variation. This population-based study used data from Norway, the four UK nations (England, Northern Ireland, Scotland, and Wales), eight Canadian provinces (Alberta, British Columbia, Manitoba, Newfoundland and
-
Data sharing in cancer research: perceived risks and the consequences of not sharing Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 James T Topham, Rita T Lawlor, Diana Lemaire, Raffaella Casolino, Andrew V Biankin
-
Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Prof Shankar Siva MBBS PhD, Mathias Bressel MSc, Mark Sidhom MBBS, Swetha Sridharan MBBS, Ben G L Vanneste MD PhD, Ryan Davey PhD, Rebecca Montgomery BBiomedSc, Jeremy Ruben MbBCh, Prof Farshad Foroudi MBBS, Braden Higgs MBBS, Charles Lin MBBS, Avi Raman MBBS MPH, Nicholas Hardcastle PhD, Prof Michael S Hofman MBBS, Richard De Abreu Lourenco PhD, Mark Shaw MBChB, Pascal Mancuso MBBS, Daniel Moon MBBS
Stereotactic ablative body radiotherapy (SABR) is a novel non-invasive alternative for patients with primary renal cell cancer who do not undergo surgical resection. The FASTRACK II clinical trial investigated the efficacy of SABR for primary renal cell cancer in a phase 2 trial. This international, non-randomised, phase 2 study was conducted in seven centres in Australia and one centre in the Netherlands
-
Paraneoplastic dermatoses in a patient with gastric adenocarcinoma: cutaneous clues to internal malignancy Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Tai-Li Chen MD, Tsung-Hsien Chang MD, Cheng-Yuan Li MD
-
Surrogate endpoints in clinical trials of p16-positive squamous cell carcinoma of the oropharynx: an individual patient data meta-analysis Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Laila A Gharzai MD, Emily Morris PhD, Krithika Suresh PhD, Phuc Felix Nguyen-Tân MD, David I Rosenthal MD, Maura L Gillison MD, Paul M Harari MD, Adam S Garden MD, Shlomo Koyfman MD, Jimmy J Caudell MD, Christopher U Jones MD, Darrion L Mitchell MD, Greg Krempl MD, John A Ridge MD, Michael F Gensheimer MD, James A Bonner MD, Edith Filion MD, Neal E Dunlap MD, William A Stokes MD, Quynh-Thu Le MD, Pedro
The increased incidence of human papillomavirus (HPV)-related cancers has motivated efforts to optimise treatment for these patients with excellent prognosis. Validation of surrogates for overall survival could expedite the investigation of new therapies. We sought to evaluate candidate intermediate clinical endpoints in trials assessing definitive treatment of p16-positive oropharyngeal cancer with
-
Antibody–drug conjugates in acute myeloid leukaemia: more research needed Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Sabine Kayser
-
Accurately addressing double-arm-zero-events studies in meta-analyses – Authors' reply Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Yu Fujiwara, Nobuyuki Horita, Abdul Rafeh Naqash
-
Accurately addressing double-arm-zero-events studies in meta-analyses Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Qi Zhou, Yaolong Chen
-
CALLA trial: immunotherapy in locally advanced cervical cancer Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Xi Yang, Yuanyuan Zhang, Shuangzheng Jia, Jusheng An, Manni Huang
-
Uncovering causal clues in the development of second primary cancers Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Huan Yi, Jianguang Ji
-
Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody–drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Prof Naval G Daver MD, Pau Montesinos MD, Prof Daniel J DeAngelo MD, Prof Eunice S Wang MD, Nikolaos Papadantonakis MD, Elisabetta Todisco MD, Kendra L Sweet MD, Prof Naveen Pemmaraju MD, Andrew A Lane MD, Laura Torres-Miñana MD, James E Thompson MD, Prof Marina Y Konopleva MD, Callum M Sloss PhD, Krystal Watkins MS, Gaurav Bedse PhD, Yining Du PhD, Kara E Malcolm RN, Patrick A Zweidler-McKay MD, Prof
Pivekimab sunirine (IMGN632) is a first-in-class antibody–drug conjugate comprising a high-affinity CD123 antibody, cleavable linker, and novel indolinobenzodiazepine pseudodimer payload. CD123 is overexpressed in several haematological malignancies, including acute myeloid leukaemia. We present clinical data on pivekimab sunirine in relapsed or refractory acute myeloid leukaemia. This first-in-human
-
CALLA trial: immunotherapy in locally advanced cervical cancer Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Fadila Kouhen, Mohammed Sqali Houssaini
-
Deep-learning-based reconstruction of undersampled MRI to reduce scan times: a multicentre, retrospective, cohort study Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Aditya Rastogi PhD, Gianluca Brugnara MD, Martha Foltyn-Dumitru MD, Mustafa Ahmed Mahmutoglu MD, Chandrakanth J Preetha MSc, Erich Kobler PhD, Irada Pflüger MD, Marianne Schell MD, Katerina Deike-Hofmann MD, Tobias Kessler MD, Prof Martin J van den Bent MD, Ahmed Idbaih MD, Prof Michael Platten MD, Prof Alba A Brandes MD, Prof Burt Nabors MD, Prof Roger Stupp MD, Denise Bernhardt MD, Prof Jürgen Debus
The extended acquisition times required for MRI limit its availability in resource-constrained settings. Consequently, accelerating MRI by undersampling k-space data, which is necessary to reconstruct an image, has been a long-standing but important challenge. We aimed to develop a deep convolutional neural network (dCNN) optimisation method for MRI reconstruction and to reduce scan times and evaluate
-
Radiotherapy trial quality assurance processes: a systematic review Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Chloe Brooks FRCR, Elizabeth Miles MPhil, Prof Peter J Hoskin MD
Quality assurance remains a neglected component of many trials, particularly for technical interventions, such as surgery and radiotherapy, for which quality of treatment is an important component in defining outcomes. We aimed to evaluate evidence for the processes used in radiotherapy quality assurance of clinical trials. A systematic review was undertaken focusing on use of a pre-trial outlining
-
Non-surgical ablation for breast cancer: an emerging therapeutic option Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Masakazu Toi MD PhD, Takayuki Kinoshita MD, John R Benson MD, Prof Ismail Jatoi MD, Masako Kataoka MD, Prof Wonshik Han MD, Chikako Yamauchi MD, Takashi Inamoto MD, Masahiro Takada MD
Non-surgical ablation is emerging as an alternative local therapy option for patients with early-stage breast cancer and encompasses two main types of percutaneous therapeutic procedures: radiofrequency ablation and cryoablation. Both techniques involve obliteration of a spherical lesion and feasibility studies have shown that complete tumour ablation is achievable with good or excellent cosmetic results
-
Lessons learned from postmarketing withdrawals of expedited approvals for oncology drug indications Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Simone N Koole PhD, Atse H Huisman PharmD, Lonneke Timmers PhD, Hans M Westgeest PhD, Edwin van Breugel MD, Prof Gabe S Sonke PhD, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani PhD
In the past decade, there have been a record number of oncology therapy approvals by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Besides the EMA's conditional marketing authorisation programme and the FDA's Accelerated Approval Program, we observe a tendency towards fast approval for exploratory studies with non-randomised, uncontrolled designs and surrogate endpoints
-
68Ga-RM2 PET–MRI versus MRI alone for evaluation of patients with biochemical recurrence of prostate cancer: a single-centre, single-arm, phase 2/3 imaging trial Lancet Oncol. (IF 51.1) Pub Date : 2024-02-26 Heying Duan MD, Farshad Moradi MD, Guido A Davidzon MD, Tie Liang EdD, Hong Song MD, Andreas M Loening MD, Prof Shreyas Vasanawala MD, Prof Sandy Srinivas MD, Prof James D Brooks MD, Prof Steven Hancock MD, Prof Andrei Iagaru MD
National Comprehensive Cancer Network guidelines include prostate-specific membrane antigen (PSMA)-targeted PET for detection of biochemical recurrence of prostate cancer. However, targeting a single tumour characteristic might not be sufficient to reflect the full extent of disease. Gastrin releasing peptide receptors (GRPR) have been shown to be overexpressed in prostate cancer. In this study, we